Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
from Top Health News -- ScienceDaily https://ift.tt/317NlC5
from Top Health News -- ScienceDaily https://ift.tt/317NlC5
Comments
Post a Comment